Table II.

Longitudinal Analysis of the Relation Among BMI, Use of Inhaled Budesonide, and Measures of Lung Function

	P-values from adjusted longitudinal analysisll
	FEV1 (%pred)*	FEV1/FVC*	BDR
Time†	<0.0001	<0.0001	<0.0001
Budesonide‡	<0.0001	<0.0001	<0.0001
BMI (percentile)	<0.0001	0.001	0.04
BMI* budesonide	0.15	0.0007	0.049
Gender	<0.0001	<0.0001	0.36
Age (years)	0.02	0.29	0.29
Height (cm)	0.002	0.003	0.4
Duration of asthma	0.07	0.004	0.005
Tobacco exposure	0.02	0.91	0.6
Race§: African-American	0.56	0.19	0.01
Hispanic/Other	0.009	0.96	0.43
Vitamin D (log10)	0.03	0.92	0.17

Shown are the P-values for each variable from the adjusted longitudinal analysis. The interaction between BMI (as a continuous variable) and treatment with budesonide is highlighted in grey. Both budesonide and BMI had significant effects on all three lung function measures (P<0.05), as do some of the covariates. There was a significant interaction between budesonide treatment and BMI (budesonide*BMI) for FEV₁/FVC and for BDR.

^*Pre-bronchodilator FEV₁ and FEV₁/FVC.

^†As months of follow-up during CAMP.

^‡Effect of budesonide compared to placebo/nedocromil.

^§Compared to non-Hispanic whites.

^||All models were adjusted for all of the variables listed in the first column.